Jul. 16 at 1:30 PM
$MU will supply the high-bandwidth memory and advanced AI infrastructure needed to accelerate
$OKUR computational chemistry platform. The real-world use case would be faster molecular simulations, larger virtual drug screens, and more rapid optimization of mutation-selective cancer therapies—potentially helping
$OKUR identify stronger PI3Kα candidates while reducing development time and cost!
$OKUR already has two next-generation programs, OKI-355 and OKI-345, moving toward planned IND submissions in the first half of 2027, plus approximately
$192 million in cash and an expected runway into 2029. The
$MU partnership will give OnKure the computing and memory backbone to scale AI-driven precision medicine across breast cancer, vascular anomalies, and future pipeline targets 🧬🧠🚀
